10-Q/A: Immix Biopharma Files Amended Quarterly Report to Include Executive Certifications

Immix Biopharma files an amendment to its original Q1 2025 report to include certifications from the CEO and CFO as required by Sarbanes-Oxley Act.

Summary

• Immix Biopharma, Inc. filed an amendment to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.
• The amendment was filed to include certifications of the Principal Executive Officer and Principal Financial Officer, which were inadvertently omitted from the original report.
• The certifications are furnished as exhibits to the amendment.
• No other changes were made to the original Form 10-Q, and the amendment speaks as of the original filing date.
• The company had 27,877,293 shares of common stock outstanding as of May 6, 2025.

Sentiment

Score: 7

Explanation: The document is a routine amendment to correct an oversight in the original filing, indicating a neutral to slightly positive sentiment as the company is addressing compliance issues promptly.

Positives

• The company is taking corrective action to ensure compliance with SEC regulations by including the required certifications.

Negatives

• The original filing was incomplete due to the omission of required certifications.

Risks

• The omission of certifications in the original filing could raise concerns about internal controls and compliance procedures.

Future Outlook

The amendment does not contain any forward-looking statements; it only addresses the omission of certifications in the original filing.

Management Comments

• Ilya Rachman, CEO, certifies that the report does not contain untrue statements or omissions of material facts.
• Gabriel Morris, CFO, certifies that the report does not contain untrue statements or omissions of material facts.
• Both the CEO and CFO certify that the report complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and fairly presents the company's financial condition and results of operations.

Industry Context

This is a standard regulatory filing update to ensure compliance with financial reporting requirements, which is common for publicly traded companies.

Comparison to Industry Standards

• The amendment addresses a procedural requirement related to executive certifications, which is a standard practice for publicly traded companies like Immix Biopharma.
• Comparable companies also file similar amendments to ensure compliance with SEC regulations and maintain investor confidence.

Stakeholder Impact

• The amendment ensures that stakeholders receive a complete and accurate financial report, enhancing transparency and trust.

Key Dates

Keywords

Form 10-Q/A, amendment, certifications, Sarbanes-Oxley, financial reporting, IMMX, Immix Biopharma, quarterly report